8 results about "Interstitial cystitis" patented technology

The application discloses application of metformin in preparation of a medicine for treating interstitial cystitis, and finds that metformin can reduce pain sensitivity of an interstitial cystitis (IC) rat, reduce edema degree of a bladder of the IC rat, restore bladder capacity of the IC rat, repair the bladder mucosa of the IC rat and reduce submucosal hemorrhage, reduce mast cell infiltration, and has a significant curative effect on interstitial cystitis, and can provide a new medicine for treating interstitial cystitis.

The invention provides a compound of formula (I): or a salt thereof, wherein R1-R7 and X have any of the values described in the specification, as well as compositions comprising a compound of formula (I) or a salt thereof. The compounds and salts are useful for activating a focal adhesion kinase (FAK) and for treating epithelial disease or damage. The invention also provides methods to treat bladder disease and damage, interstitial cystitis and transplant corneas with compounds discussed in herein.

To provide methods and kits for identifying a companion animal having an increased risk of developing interstitial cystitis; along with compositions for treating the same.SOLUTION: A pet food composition comprises an effective amount of a fiber-bound polyphenol component, for use in increasing the level of a urinary cytokine selected from: Fms-like tyrosine kinase 3 (F1t3-L), a stem cell factor (SCF); and IL-12p40, in a companion animal.SELECTED DRAWING: Figure 1A

The invention relates to the use of epidermal growth factor for the manufacture of a medicament for the treatment of interstitial cystitis. The "epidermal growth factor" (EGF) of the invention can be used to manufacture an excellent medicament for interstitial cystitis. The medicament has a composition that includes an active ingredient, adjuvant, dispersant, wetting agent, and / or suspension agent. The carrier of the epidermal growth factor is water, colloid, hyaluronic acid, natural oils, and / or glucose. The medicament serves to reduce urinary frequency. The medicament serves to restore bladder elasticity. The medicament serves to reduce cystitis. The medicament serves to increase the antioxidant capacity in bladder tissue.The present invention proposes a novel effect of epidermal growth factor, which can be used to treat interstitial cystitis and to repair the bladder mucosa and exhibits excellent efficacy.

The invention provides a method of treating interstitial cystitis that applies therapeutic exomes to the bladder of a patient through intravesical administration. Unlike the intravesical administration of stem cells, the intravesical administration of exosomes permits a therapeutic amount of paracrine-active growth factors and cytokines to be applied to bladder tissue before they can voided by urination.

The invention discloses interstitial cystitis serum polypeptide marker human serum albumin and application thereof, and belongs to the technical field of medical detection. The polypeptide is a fragment of human albumin (Albumin, ALB), the amino acid sequence of the polypeptide is as shown in SEQ.ID.NO.1, and the accurate molecular weight of the polypeptide is 1467.8 Daltons. The detection value range of the compound in the serum of normal people is 0.2499-4.8150 mg / mL, the detection value range of the compound in the serum of interstitial cystitis patients is 5.2170-9.7240 mg / mL, the compound in the serum of the patients is remarkably highly expressed, and the inter-group difference is extremely remarkable (plt; aLB can be used as a basis for preparation of interstitial cystitis diagnosis medicines and a serum diagnosis medicine target, and a new direction is provided for development of diagnosis means; the interstitial cystitis serum diagnostic drug contains a reagent capable of specifically detecting ALB, and can quantitatively or qualitatively detect ALB. The polypeptide can also be used as a target molecule for ELISA (enzyme-linked immuno sorbent assay) detection, and is beneficial to timely and accurate diagnosis of interstitial cystitis.

The invention belongs to the technical field of exosome application, and discloses a triptolide-loaded nano co-delivery drug delivery carrier and application thereof in preparation of drugs for treating interstitial cystitis. The triptolide-loaded nano co-delivery drug delivery carrier is used for interstitial cystitis model animals, and the following changes are observed: 1, the sensitivity of the model animals to stimulation is reduced; 2, the urination frequency of model animals is reduced, and the urination volume of words is increased; 3, the number of red blood cells in urine of the model animal is reduced; 4, bladder tissue hyperemia is relieved, and the size is reduced; and 5, the expression of inflammatory factors IL-6, MCP-1, ICAM-1 and BAX is obviously reduced. Therefore, it can be determined that the triptolide-loaded nano-co-delivery drug delivery carrier is used for treating interstitial cystitis. According to the research, the application range of the triptolide is expanded, and the triptolide is combined with the exosome to be used for treating the interstitial cystitis, so that a new thought is provided for treating the interstitial cystitis.

The invention discloses nano-silver polyphenol-recombinant humanized collagen bionic gel for interstitial cystitis, belongs to the field of biomedical materials and regenerative medicine, and particularly relates to a novel biomedical composite gel material. Especially aiming at the pathological characteristics of interstitial cystitis IC, silver nanoparticles, a surface polyphenol network and PDA-amine functionalized combination III type recombinant humanized collagen and a sodium alginate matrix are crosslinked through EDC / NHS or Genipin to construct a stable sustained-release system; the prepared gel shows excellent antibacterial activity, cytocompatibility, appropriate rheological properties and swelling rate in vitro, is controllable in degradation half-life period, can significantly improve frequent urination, reduce inflammation score and recover bladder capacity in an animal model, and is suitable for cystitis local perfusion treatment.